KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Liabilities and Shareholders Equity (2016 - 2025)

Sarepta Therapeutics has reported Liabilities and Shareholders Equity over the past 16 years, most recently at $3.3 billion for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 15.48% year-over-year to $3.3 billion; the TTM value through Dec 2025 reached $14.0 billion, down 1.57%, while the annual FY2025 figure was $3.3 billion, 15.48% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $3.3 billion at Sarepta Therapeutics, down from $3.5 billion in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $4.0 billion in Q4 2024 and troughed at $2.7 billion in Q3 2021.
  • A 5-year average of $3.2 billion and a median of $3.2 billion in 2021 define the central range for Liabilities and Shareholders Equity.
  • Biggest five-year swings in Liabilities and Shareholders Equity: rose 21.4% in 2024 and later fell 15.48% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $3.1 billion in 2021, then fell by 0.62% to $3.1 billion in 2022, then rose by 4.35% to $3.3 billion in 2023, then increased by 21.4% to $4.0 billion in 2024, then fell by 15.48% to $3.3 billion in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for SRPT at $3.3 billion in Q4 2025, $3.5 billion in Q3 2025, and $3.7 billion in Q2 2025.